CWAM
CBAY

Columbia Wanger Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Columbia Wanger Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-228
Closed -$2K – 287
2014
Q3 		$2K Buy
+228
New +$1.4K ﹤0.01% 280

Other funds holding CBAY

LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Columbia Wanger Asset Management's CBAY Position: Q4 2014 in Review

Columbia Wanger Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2014, closing a stake of 228 shares — an estimated $2K sold.

Columbia Wanger Asset Management first reported a position in CBAY in Q3 2014 and held it in 1 quarter. The position peaked at $2K in Q3 2014. 26 funds tracked by Wall St. Rank hold CBAY as of Q4 2014.

  • Columbia Wanger Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Columbia Wanger Asset Management sold 228 Cymabay Therapeutics shares in Q4 2014, an estimated $2K.
  • Columbia Wanger Asset Management first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 1 quarter.
  • Columbia Wanger Asset Management's Cymabay Therapeutics position peaked at $2K in Q3 2014.
  • 26 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2014.

Based on Columbia Wanger Asset Management's 13F filing for Q4 2014, filed 6 Feb 2015.